clozapine. The total score of Adverse Drug Reaction Probability Scale is 7. The urinary retention didn't respond to bethanechol (a cholinergic agent) and tamsulosin (a selective α1 receptor antagonist), and it resolved completely after discontinuation of clozapine while haloperidol 10 mg/day was kept. Discussion and conclusions: Anticholinergic effect of clozapine has been suspected to contribute to impaired detrusor muscle contraction and therefore urinary retention, however, the urodynamic study in the case reported showed normal detrusor function during filling and voiding. Treatment with cholinergic agent didn't improve urinary retention as well. This case report highlights that urinary retention can be an uncommon adverse effect of clozapine and may not be merely resulted from anticholinergic effect.
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LONG-TERM ANTIPSYCHOTICS IN "HYSTERICAL PSYCHOSIS": A CASE REPORT
INTRODUCTION:
Once known as hysterical psychosis, K. Jaspers described the concept of a Reactive Psychosis in 1913, including presence of an identifiable traumatic stressor. Psychotic symptoms (delusion, speech disorders and hallucinations) can be triggered by stressful life events. The condition usually resolves spontaneously within a time span of weeks and if it is controlled well enough that symptoms do not return. This case report illustrates the effectiveness of long-term Aripiprazole in treatment of a "Hysterical Psychosis" METHODS: CASE REPORT: Male patient, 24 years old, referred for psychiatric follow-up after discharge from the psychiatry ward. Paranoid delusion was detected 2 weeks before admission. He was reported as Acute Psychosis with good response to Aripiprazole orally (15 mg per day) and Lorazepam, with total remission of positive psychotic symptoms. Sexual identity stressor was identified during admission and no history of mental disease had been reported. After a 6 weeks follow-up, the patient decided to quit medication and two weeks later, psychotic symptoms returned as well as sexual identity problems. Aripiprazole orally was prescribed again. RESULTS: After reintroducing Aripiprazole orally with good response and, given the patient personality (cluster B), we decided to use long-term Aripiprazole (300 mg per month) to ensure compliance. The patient made a rapid recovery and kept asymptomatic for 3 months. Treatment included psychodynamic psychotherapy. Antipsychotic was retired after this time and no relapse was informed. DISCUSSION AND CONCLUSIONS: Classical psychiatric conditions lack the necessary support in current diagnostic classifications to fulfil criteria for using antipsychotic drugs according to approved indications. Papers showing drugs effectiveness for classical terms are difficult to find. This poster is made with the aim to open investigation to those conditions not fitting current diagnostic criteria.
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Paliperidone Palmitate 3-Monthly vs. : PP1M or PP3M), TTO and TTR, and descriptively compared. TTO and TTR were further analyzed by final OL dose (50/75 mg eq., 100 mg eq. and 150 mg eq.) and age (18-25, 26-50 and 50+ years) subgroups. Results: Overall incidence of EPS-related AEs was 12.6% (PP1M) during OL phase, reducing to 8.3% (PP3M) and 7.4% (PP1M) during DB phase. Median TTO for all EPS-related AEs was 17 days (range: 1-120) after PP1M OL treatment; 115 days (range: 1-323) and 98.5 days (range: 1-322) after treatment with PP3M and PP1M, respectively (DB phase). Median TTR was 36.5 days (range: 1-127) in PP1M group (OL), and was generally similar for PP3M (91 days [range: 1-336]) vs. PP1M (85.5 days [range: 1-337]) during DB phase. Overall median TTO and TTR values were comparable between PP3M and PP1M formulations. Subgroup analysis revealed no clear dose-response or age-related differences in TTO and TTR of EPS-events for the two formulations. Discussion: The overall incidence of EPS-related AEs, TTO and TTR of EPS-events were found to be comparable in patients with schizophrenia receiving either PP3M or PP1M long-acting injectable. Methods: Post hoc analysis of a randomized, double-blind (DB), parallel-group, multicenter, noninferiority study (NCT01515423). Subjects with schizophrenia were treated with PP once-monthly (PP1M) in a 17-week open-label (OL) phase. Upon meeting clinical stabilization criteria, they were randomized 1:1 to PP1M or PP once-every-3-months (PP3M) in a 48-week relapse-prevention phase. Subjects were evaluated based on duration of illness (≤5, 6-10, and >10 years since diagnosis); PP1M and PP3M results were combined. Positive and Negative Syndrome Scale (PANSS) and Personal and Social Performance (PSP) scale scores and functional remission rates (PSP >70 from week 13 [OL] and during DB phase for ≥6 months) were analyzed. No adjustment was made for multiplicity. Results: 532, 337, and 558 subjects diagnosed with schizophrenia ≤5, 6-10, and >10 years ago, respectively, entered OL phase. Of these, 379 (71.2%), 235 (69.7%), and 380 (68.1%) met clinical stabilization criteria and entered DB phase. Significant differences were observed in the ≤5 and 6-10 groups versus the >10 group from DB baseline to DB endpoint for PANSS and PSP total scores (P<0.03 for all). More patients achieved functional remission in the ≤5 (26.4%) and 6-10 (30.2%) groups versus the >10 group (18.6%). Conclusion: Improvements were observed with PP LAIs in all subgroups, with greater improvements among patients earlier in the illness (<5 or 5-10 years) compared to those with more chronic illness (>10 years). Support: Janssen Scientific Affairs, LLC
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Emergence of Tardive Dyskinesia upon Clozapine Treatment: A Case Report
